India, April 14 -- Medical products and technologies company Convatec Group Plc (CTEC.L,CNVVY) Monday announced that it has raised its sales outlook of InnovaMatrix for fiscal 2025, after the U.S. Centers for Medicare & Medicaid Services or CMS postponed Local Coverage Determinations or LCDs in the United States.
The federal agency last Friday announced the postponement of the LCDs for Skin Substitute Grafts/Cellular and Tissue-Based Products for the treatment of Diabetic Foot Ulcers or DFUs and Venous Leg Ulcers or VLUs.
According to Convatec, the action by the US Administration means that Medicare patients with DFUs and VLUs will continue to benefit from access to InnovaMatrix.
The company now expects InnovaMatrix sales of approximatel...